Christine Mateus
Institut Gustave Roussy · 296 works · 33,267 citations · h-index 54
Top works
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Kidney injuries related to ipilimumab
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
- Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
- RAF inhibition and induction of cutaneous squamous cell carcinoma
- A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS , TP53 , and TGFBR1